Abstract FR598: Impact of Renal Denervation with Symplicity Spyral on Hypertension Management Stratified by Obesity: Findings from a Pilot Study in Kuwait

Introduction/Background: Renal denervation (RDN) is an emerging therapy shown to significantly reduce BP. Research Questions/Hypothesis: Impact of RDN on obese hypertensive Patients are unknown. Goals/Aims: Aim of our study to analyze the Impact of RDN on obese hypertensive patients. Methods/Approach: Patients were stratified into 2 groups Obese and non obese. Pre- and post-procedural. BP measurements were analyzed using repeated measures ANOVA to assess the changes in systolic (SYS) and diastolic (DIA) BP over time. Results/Data (descriptive and inferential statistics): This retrospective study included 50 hypertensive patients who underwent RDN with Symplicity Spyral from March 2023 to August 2024. The cohort had a mean age of 61.7 years. Pre-RDN mean SYS and DIA BP were 163.7 mmHg and 86.7 mmHg, respectively. The impact of renal denervation on blood pressure (BP) was examined in obese and non-obese groups. Initially, the non-obese group had a higher SYS BP (180 mmHg) compared to the obese group (160 mmHg). Post-RDN, SYS BP decreased to 145 mmHg in the non-obese group and to 140 mmHg in the obese group. Six months post-RDN, SYS BP stabilized at around 140 mmHg in both groups. RDN effectively reduced and maintained lower SYS BP in both groups over six months.The forest plot analysis showed that Dyslipidemia (DLP) significantly reduced the odds of achieving the SYS BP target (OR = 0.17, p = 0.036). Both regression lines showed strong fits (SYS BP: R 2 = 0.8277; DIA BP: R 2 = 0.997). Repeated Measures ANOVA indicated significant changes in SYS BP over time (p < .001, η 2 p = 0.590), with significant interaction between time and BMI category (p = 0.038). Logistic regression analysis highlighted DLP as a significant predictor, reducing the likelihood of achieving the systolic BP Target (OR = 0.17, p = 0.036). Other factors like BMI, age, CKD, and EF% were not significant predictors. Conclusion(s): Renal denervation (RDN) with Symplicity Spyral effectively reduces blood pressure in both obese and non-obese individuals, with sustained improvements over six months. Dyslipidemia significantly decreases the likelihood of achieving target BP, while other factors such as BMI, age, chronic kidney disease (CKD), and ejection fraction percentage (EF%) are not significant predictors. These findings support the use of RDN as a viable intervention for managing hypertension, highlighting the importance of addressing dyslipidemia in hypertensive patients.